StreetInsider.com News Articles

Form 8-K Cocrystal Pharma, Inc. For: Jul 31

Mon, 03 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26853840.html

Form 8-K Cocrystal Pharma, Inc. For: Jul 31

Mon, 03 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260803/26853840.html

Opko Health invests $5M in Cocrystal Pharma via private placement

Mon, 03 Aug 2026 07:00:12 -0400

Cocrystal Pharma (NASDAQ: COCP) announced a $5 million private placement with OPKO Health (NASDAQ: OPK), under which OPKO purchased 5,474,053 shares of Cocrystal common stock at $0.9134 per share, based on the Nasdaq Consolidated Bid Price on the trading day of closing. No warrants or other derivative securities were included in the transaction.

The shares were sold as unregistered securities under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. OPKO is described in the press release as a longtime investor in Cocrystal.

James Sapirstein, Chief Executive Officer of Cocrystal Pharma, said the company expects to report topline data from

Opko Health invests $5M in Cocrystal Pharma via private placement

Mon, 03 Aug 2026 07:00:12 -0400

The shares were sold as unregistered securities under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. OPKO is described in the press release as a longtime investor in Cocrystal.

James Sapirstein, Chief Executive Officer of Cocrystal Pharma, said the company expects to report topline data from

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Mon, 03 Aug 2026 07:00:00 -0400

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026

BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus program toward Phase 1b topline data later this year.

Under the terms of the agreement, Cocrystal

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Mon, 03 Aug 2026 07:00:00 -0400

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026

Under the terms of the agreement, Cocrystal

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Mon, 03 Aug 2026 07:00:00 -0400

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026

Under the terms of the agreement, Cocrystal

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Mon, 03 Aug 2026 07:00:00 -0400

Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026

Under the terms of the agreement, Cocrystal

Form 8-K Cocrystal Pharma, Inc. For: Jul 14

Fri, 17 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260717/26782104.html

Form 8-K Cocrystal Pharma, Inc. For: Jul 14

Fri, 17 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260717/26782104.html

Form 8-K Cocrystal Pharma, Inc. For: Jun 03

Tue, 09 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260609/26620081.html

Form 8-K Cocrystal Pharma, Inc. For: Jun 03

Tue, 09 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260609/26620081.html

Form 4 Cocrystal Pharma, Inc. For: Jun 03 Filed by: SAPIRSTEIN JAMES

Wed, 03 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260603/26598915.html

Form 4 Cocrystal Pharma, Inc. For: Jun 03 Filed by: SAPIRSTEIN JAMES

Wed, 03 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260603/26598915.html

Form 3 Cocrystal Pharma, Inc. For: Jun 03 Filed by: SAPIRSTEIN JAMES

Wed, 03 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260603/26598898.html

Form 3 Cocrystal Pharma, Inc. For: Jun 03 Filed by: SAPIRSTEIN JAMES

Wed, 03 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260603/26598898.html

Cocrystal Pharma names James Sapirstein as chief executive officer

Wed, 03 Jun 2026 07:03:24 -0400

Cocrystal Pharma Inc. (NASDAQ: COCP) appointed James Sapirstein as chief executive officer, effective immediately, according to a company statement. The biotechnology company also plans to add Sapirstein to its board of directors.

Sapirstein replaces Sam Lee and Jim Martin, who previously served as co-chief executive officers. Lee will continue as president and transition to chief scientific officer, while Martin will remain as chief financial officer.

The new CEO brings experience from leadership roles at several pharmaceutical companies. He previously served as chief executive officer of Contravir Pharmaceuticals and founding chief executive officer of Tobira Therapeutics. Sapirstein also held the position of executive

Cocrystal Pharma names James Sapirstein as chief executive officer

Wed, 03 Jun 2026 07:03:24 -0400

Cocrystal Pharma names James Sapirstein as chief executive officer

Wed, 03 Jun 2026 07:03:24 -0400

Cocrystal Pharma names James Sapirstein as chief executive officer

Wed, 03 Jun 2026 07:03:24 -0400

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer